Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer

Hohmann, Lennart LU orcid ; Nacer, Deborah F. LU orcid ; Aine, Mattias LU ; Memari, Yasin ; Black, Daniella ; Bowden, Ramsay ; Davies, Helen R. ; Borg, Åke LU ; Vallon-Christersson, Johan LU orcid and Nik-Zainal, Serena , et al. (2025) In Genome Medicine 17(1).
Abstract

Background: The clinical management of ER-positive/HER2-negative (ERpHER2n) breast cancer is complicated by a heterogeneous patient population, with some patients exhibiting endocrine resistance and an increased risk of recurrence. Among these high-risk subgroups, ERpHER2n Basal-like (ERpHER2n-Basal) breast cancer, as defined by PAM50 gene expression subtyping, remains poorly characterized due to limited available material. However, understanding the somatic molecular features driving treatment resistance and progression is critical for optimizing therapy. Methods: To address these challenges, we comprehensively characterized the patient subgroup by comparing it to both ERpHER2n and triple-negative breast cancer (TNBC) patients. We... (More)

Background: The clinical management of ER-positive/HER2-negative (ERpHER2n) breast cancer is complicated by a heterogeneous patient population, with some patients exhibiting endocrine resistance and an increased risk of recurrence. Among these high-risk subgroups, ERpHER2n Basal-like (ERpHER2n-Basal) breast cancer, as defined by PAM50 gene expression subtyping, remains poorly characterized due to limited available material. However, understanding the somatic molecular features driving treatment resistance and progression is critical for optimizing therapy. Methods: To address these challenges, we comprehensively characterized the patient subgroup by comparing it to both ERpHER2n and triple-negative breast cancer (TNBC) patients. We investigated 4474 Swedish patients with primary ERpHER2n tumors (Basal-like = 76, Luminal A = 3049, Luminal B = 1349) with clinical and RNA-sequencing data available, including 16 Basal-like tumors with whole-genome sequencing and matched global DNA methylation data. For TNBC comparisons, we used an additional 228 cases with available WGS, RNA-sequencing, and DNA methylation data. ER-positivity was defined as ≥ 10% of tumor cells being IHC-stained according to Swedish national guidelines. Results: Clinicopathological analyses highlighted ERpHER2n-Basal patients as a small subgroup comprising generally younger patients with high-grade and high-risk tumors. This patient group was associated with worse prognosis than Luminal A/Luminal B subtypes, especially when treated only with endocrine therapy, independent of lymph node status, patient age, tumor size and grade. Molecularly, ERpHER2n-Basal tumors were distinguished by high proliferation and elevated immune response together with low ESR1 mRNA expression and low activity of steroid-response pathways. High proportions of the mutational signatures associated with homologous recombination deficiency in ERpHER2n-Basal tumors suggest potential benefits from platinum or PARP inhibitor treatments. Additionally, their DNA methylation profile closely resembles that of Basal triple-negative breast cancer (TNBC), indicating shared epigenetic regulation despite differences in ER status. Further molecular similarities to TNBC such as high immune infiltration indicate immune checkpoint inhibitors as promising agents for improving patient care. Conclusions: ERpHER2n-Basal breast cancer represents a clinically high-risk subgroup whose molecular resemblance to TNBC highlights potential therapeutic opportunities, particularly for immunotherapy and DNA repair–targeting treatments.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Basal phenotype, DNA methylation profile, ER-positive/HER2-negative breast cancer, Gene expression profiling, High-risk breast cancer, Homologous recombination deficiency, PAM50 subtyping
in
Genome Medicine
volume
17
issue
1
article number
146
publisher
BioMed Central (BMC)
external identifiers
  • pmid:41327380
  • scopus:105023453673
ISSN
1756-994X
DOI
10.1186/s13073-025-01576-9
language
English
LU publication?
yes
id
bfe25928-7c44-4b9b-9dfe-5490837840e1
date added to LUP
2026-01-14 11:45:54
date last changed
2026-01-15 03:44:42
@article{bfe25928-7c44-4b9b-9dfe-5490837840e1,
  abstract     = {{<p>Background: The clinical management of ER-positive/HER2-negative (ERpHER2n) breast cancer is complicated by a heterogeneous patient population, with some patients exhibiting endocrine resistance and an increased risk of recurrence. Among these high-risk subgroups, ERpHER2n Basal-like (ERpHER2n-Basal) breast cancer, as defined by PAM50 gene expression subtyping, remains poorly characterized due to limited available material. However, understanding the somatic molecular features driving treatment resistance and progression is critical for optimizing therapy. Methods: To address these challenges, we comprehensively characterized the patient subgroup by comparing it to both ERpHER2n and triple-negative breast cancer (TNBC) patients. We investigated 4474 Swedish patients with primary ERpHER2n tumors (Basal-like = 76, Luminal A = 3049, Luminal B = 1349) with clinical and RNA-sequencing data available, including 16 Basal-like tumors with whole-genome sequencing and matched global DNA methylation data. For TNBC comparisons, we used an additional 228 cases with available WGS, RNA-sequencing, and DNA methylation data. ER-positivity was defined as ≥ 10% of tumor cells being IHC-stained according to Swedish national guidelines. Results: Clinicopathological analyses highlighted ERpHER2n-Basal patients as a small subgroup comprising generally younger patients with high-grade and high-risk tumors. This patient group was associated with worse prognosis than Luminal A/Luminal B subtypes, especially when treated only with endocrine therapy, independent of lymph node status, patient age, tumor size and grade. Molecularly, ERpHER2n-Basal tumors were distinguished by high proliferation and elevated immune response together with low ESR1 mRNA expression and low activity of steroid-response pathways. High proportions of the mutational signatures associated with homologous recombination deficiency in ERpHER2n-Basal tumors suggest potential benefits from platinum or PARP inhibitor treatments. Additionally, their DNA methylation profile closely resembles that of Basal triple-negative breast cancer (TNBC), indicating shared epigenetic regulation despite differences in ER status. Further molecular similarities to TNBC such as high immune infiltration indicate immune checkpoint inhibitors as promising agents for improving patient care. Conclusions: ERpHER2n-Basal breast cancer represents a clinically high-risk subgroup whose molecular resemblance to TNBC highlights potential therapeutic opportunities, particularly for immunotherapy and DNA repair–targeting treatments.</p>}},
  author       = {{Hohmann, Lennart and Nacer, Deborah F. and Aine, Mattias and Memari, Yasin and Black, Daniella and Bowden, Ramsay and Davies, Helen R. and Borg, Åke and Vallon-Christersson, Johan and Nik-Zainal, Serena and Staaf, Johan}},
  issn         = {{1756-994X}},
  keywords     = {{Basal phenotype; DNA methylation profile; ER-positive/HER2-negative breast cancer; Gene expression profiling; High-risk breast cancer; Homologous recombination deficiency; PAM50 subtyping}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Genome Medicine}},
  title        = {{Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer}},
  url          = {{http://dx.doi.org/10.1186/s13073-025-01576-9}},
  doi          = {{10.1186/s13073-025-01576-9}},
  volume       = {{17}},
  year         = {{2025}},
}